Last quarter (Q4 2022), Shanghai Fosun Pharmaceutical (Group) Co's total revenue was $12.34B, an increase of 3.22% from the same quarter last year. In Q4, Shanghai Fosun Pharmaceutical (Group) Co's net income was $1.28B. See Shanghai Fosun Pharmaceutical (Group) Co’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 33.68B	$ 43.95B	$ 39.01B	$ 30.31B	$ 28.59B	$ 24.92B
Cost of Revenue	$ 17.84B	$ 23.17B	$ 20.23B	$ 13.73B	$ 11.54B	$ 10.37B
Gross Profit	$ 15.84B	$ 20.78B	$ 18.78B	$ 16.57B	$ 17.04B	$ 14.55B
Operating Expense	$ 12.90B	$ 17.15B	$ 16.06B	$ 13.74B	$ 14.43B	$ 12.19B
Operating Income	$ 2.95B	$ 3.64B	$ 2.72B	$ 2.83B	$ 1.71B	$ 2.37B
Net Non Operating Interest Income Expense	$ -666.73M	$ -709.76M	$ -618.69M	$ -699.48M	$ -906.20M	$ -820.23M
Other Income Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Pretax Income	$ 3.54B	$ 4.57B	$ 6.05B	$ 4.68B	$ 4.53B	$ 3.58B
Tax Provision	$ 524.46M	$ 626.92M	$ 1.07B	$ 737.86M	$ 782.23M	$ 559.71M
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ 2.82B	$ 3.73B	$ 4.74B	$ 3.66B	$ 3.32B	$ 2.71B
Basic EPS	$ 1.08	$ 1.43	$ 1.85	$ 1.43	$ 1.30	$ 1.07
Diluted EPS	$ 1.08	$ 1.43	$ 1.85	$ 1.43	$ 1.30	$ 1.07
Basic Average Shares	$ 7.84B	$ 2.61B	$ 2.56B	$ 2.56B	$ 2.56B	$ 2.53B
Diluted Average Shares	$ 7.84B	$ 2.61B	$ 2.56B	$ 2.56B	$ 2.56B	$ 2.53B
Dividend Per Share	$ 0.56	$ 0.56	$ 0.43	$ 0.39	$ 0.32	$ 0.40
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ 1.28	$ 1.06	$ 0.87	$ 0.83
Reported Normalized Diluted E P S	$ ―	$ ―	$ 1.28	$ 1.06	$ 0.87	$ 0.83
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 30.73B	$ 40.31B	$ 36.28B	$ 27.48B	$ 25.97B	$ 22.55B
Net Income From Continuing And Discontinued Operation	$ 2.82B	$ 3.73B	$ 4.74B	$ 3.66B	$ 3.32B	$ 2.71B
Normalized Income	$ 4.77B	$ 6.11B	$ 5.22B	$ 3.17B	$ 3.19B	$ 2.64B
Interest Expense	$ 704.71M	$ 963.81M	$ 822.53M	$ 880.95M	$ 1.07B	$ 929.66M
EBIT	$ 4.25B	$ 5.54B	$ 6.88B	$ 5.56B	$ 5.60B	$ 4.51B
EBITDA	$ 4.25B	$ 7.87B	$ 8.71B	$ 7.23B	$ 7.07B	$ 5.83B

Currency in USD

Shanghai Fosun Pharmaceutical (Group) Co Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing